Multiple myeloma is a heterogenous plasma cell disorder that contains a small fraction of clonogenic stem cells, just like many other cancers. Although the exact nature and biological properties of these cells remain elusive, multiple myeloma stem cells (MMSCs) have pronounced drug resistance and are believed to be the root cause of failure of many myeloma management therapies.

We are talking to Dr William Matsui of LiveStrong Cancer Institutes to learn about the latest research on multiple myeloma stem cells and their role in novel drug development to treat multiple myeloma.